Literature DB >> 26063223

Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.

Thomas W Geisbert1, James E Strong2, Heinz Feldmann3.   

Abstract

The filoviruses, Ebola virus and Marburg virus, are zoonotic pathogens that cause severe hemorrhagic fever in humans and nonhuman primates (NHPs), with case-fatality rates ranging from 23% to 90%. The current outbreak of Ebola virus infection in West Africa, with >26 000 cases, demonstrates the long-underestimated public health danger that filoviruses pose as natural human pathogens. Currently, there are no vaccines or treatments licensed for human use. Licensure of any medical countermeasure may require demonstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infection. Substantial progress has been made over the last decade in characterizing the filovirus NHP models. However, there is considerable debate over a variety of experimental conditions, including differences among filovirus isolates used, routes and doses of exposure, and euthanasia criteria, all of which may contribute to variability of results among different laboratories. As an example of the importance of understanding these differences, recent data with Ebola virus shows that an addition of a single uridine residue in the glycoprotein gene at the editing site attenuates the virus. Here, we draw on decades of experience working with filovirus-infected NHPs to provide a perspective on the importance of various experimental conditions. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Ebola virus; Marburg virus; animal model; filovirus; nonhuman primate; treatment; vaccine

Mesh:

Substances:

Year:  2015        PMID: 26063223      PMCID: PMC4564553          DOI: 10.1093/infdis/jiv284

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells.

Authors:  K J Davis; A O Anderson; T W Geisbert; K E Steele; J B Geisbert; P Vogel; B M Connolly; J W Huggins; P B Jahrling; N K Jaax
Journal:  Arch Pathol Lab Med       Date:  1997-08       Impact factor: 5.534

2.  Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology.

Authors:  Douglas S Reed; Matthew G Lackemeyer; Nicole L Garza; Lawrence J Sullivan; Donald K Nichols
Journal:  Microbes Infect       Date:  2011-05-25       Impact factor: 2.700

3.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

4.  Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.

Authors:  Robert W Cross; Karla A Fenton; Joan B Geisbert; Hideki Ebihara; Chad E Mire; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2015-06-19       Impact factor: 5.226

5.  Development and characterization of a mouse model for Marburg hemorrhagic fever.

Authors:  Kelly L Warfield; Steven B Bradfute; Jay Wells; Loreen Lofts; Meagan T Cooper; D Anthony Alves; Daniel K Reed; Sean A VanTongeren; Christine A Mech; Sina Bavari
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

6.  Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.

Authors:  Gopi S Mohan; Wenfang Li; Ling Ye; Richard W Compans; Chinglai Yang
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

7.  Evaluation in nonhuman primates of vaccines against Ebola virus.

Authors:  Thomas W Geisbert; Peter Pushko; Kevin Anderson; Jonathan Smith; Kelly J Davis; Peter B Jahrling
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

8.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

9.  Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure.

Authors:  Masfique Mehedi; Thomas Hoenen; Shelly Robertson; Stacy Ricklefs; Michael A Dolan; Travis Taylor; Darryl Falzarano; Hideki Ebihara; Stephen F Porcella; Heinz Feldmann
Journal:  PLoS Pathog       Date:  2013-10-17       Impact factor: 6.823

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  63 in total

1.  Humanized Mice--A Neoteric Animal Disease Model for Ebola Virus?

Authors:  Joseph Prescott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2015-11-17       Impact factor: 5.226

2.  Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Authors:  John C Kash; Kathie-Anne Walters; Jason Kindrachuk; David Baxter; Kelsey Scherler; Krisztina B Janosko; Rick D Adams; Andrew S Herbert; Rebekah M James; Spencer W Stonier; Matthew J Memoli; John M Dye; Richard T Davey; Daniel S Chertow; Jeffery K Taubenberger
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 3.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

Review 4.  From bench to almost bedside: the long road to a licensed Ebola virus vaccine.

Authors:  Gary Wong; Emelissa J Mendoza; Francis A Plummer; George F Gao; Gary P Kobinger; Xiangguo Qiu
Journal:  Expert Opin Biol Ther       Date:  2017-11-17       Impact factor: 4.388

5.  A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.

Authors:  Courtney Woolsey; Andrea R Menicucci; Robert W Cross; Priya Luthra; Krystle N Agans; Viktoriya Borisevich; Joan B Geisbert; Chad E Mire; Karla A Fenton; Allen Jankeel; Sneha Anand; Hideki Ebihara; Thomas W Geisbert; Ilhem Messaoudi; Christopher F Basler
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

Review 6.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

7.  An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.

Authors:  Dapeng Li; Tan Chen; Yang Hu; Yu Zhou; Qingwei Liu; Dongming Zhou; Xia Jin; Zhong Huang
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 8.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

9.  An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.

Authors:  Reed F Johnson; Drishya Kurup; Katie R Hagen; Christine Fisher; Rohan Keshwara; Amy Papaneri; Donna L Perry; Kurt Cooper; Peter B Jahrling; Jonathan T Wang; Jan Ter Meulen; Christoph Wirblich; Matthias J Schnell
Journal:  J Infect Dis       Date:  2016-07-24       Impact factor: 5.226

10.  Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.

Authors:  Andrea Marzi; Patrick W Hanley; Elaine Haddock; Cynthia Martellaro; Gary Kobinger; Heinz Feldmann
Journal:  J Infect Dis       Date:  2016-08-05       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.